The Genetic Pivot: How Biotech is Rewriting the Rules of the 2026 PipelineGlobal Report·6 hours agoCRVS-0.07%NVAX-1.92%
Novavax Inc. Stock Underperforms Friday When Compared To CompetitorsMarketWatch Automated·Aug 14 at 04:29 PMNVAX-1.92%
The Unbundling of Biotech: What Novavax Reveals About the Post-Pandemic Value ChainGlobal Report·Aug 11 at 05:12 AMNVAX-1.92%
Cross-Sector M&A Accelerates: Key Moves in Precision Meds and MineralsGlobal Report·Aug 11 at 04:43 AMWM+1.04%PSNL+0.36%
Novavax (NASDAQ:NVAX) Lowered to Hold Rating by Zacks ResearchMarket Beat·Aug 8 at 06:30 AMNVAX-1.92%
Novavax Inc. Stock Outperforms Competitors On Strong Trading DayMarketWatch Automated·Aug 7 at 04:26 PMNVAX-1.92%
Novavax (NASDAQ:NVAX) Posts Earnings Results, Beats Estimates By $0.06 EPSMarket Beat·Aug 6 at 10:26 PMNVAX-1.92%
Novavax Slips To Loss In Q2 On Reduced Revenue, Cuts FY26 Guidancerttnews·Aug 6 at 08:39 AMNVAX-1.92%
Novavax Q2 2026 earnings: Revenue falls as prior-year payments roll offTradingKey·Aug 6 at 07:34 AMNVAX-1.92%
Novavax | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 56.7 MEarnings Watch·Aug 6 at 07:05 AMNVAX-1.92%
Novavax Q2 FY26 turns to net loss of $53.39 million; revenue drops 76.29% to $56.7 millionPUBT·Aug 6 at 06:54 AMNVAX-1.92%SNY+1.04%
